NCT01130194View on ClinicalTrials.gov

Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Follicular Lymphoma
Interventions
OTHER

Combination of treatment modalities

"Intravenous cyclophosphamide, rituximab, and vincristine day 1 and 8 of 28 day cycles for 6 cycles total.~Oral prednisone and procarbazine day 1-14 of every 28 day cycle. Yttrium ibritumomab tiuxetan intravenous injection. Autologous stem cell transplant with intravenous BEAM (BCNU or carmustine, etoposide, ara-C or cytarabine, melphalan) chemotherapy conditioning."

Trial Locations (1)

63110

Saint Louis University Cancer Center, St Louis

All Listed Sponsors
lead

St. Louis University

OTHER

NCT01130194 - Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma | Biotech Hunter | Biotech Hunter